Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411488 | 1.00 | KMT2A (0.56) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL31000548 | 0.89 | HDAC1 (0.54) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL11912033 | 0.89 | HDAC1 (0.54) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL29397673 | 0.89 | HDAC1 (0.54) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL13402442 | 0.89 | HDAC1 (0.54) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL28527138 | 0.89 | HDAC1 (0.54) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL13411458 | 0.89 | HDAC1 (0.59) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL30480376 | 0.89 | HDAC1 (0.59) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL13411489 | 0.89 | HDAC1 (0.51) | KMT2AHDAC1HDAC2IDO1MDM4 | |
| SCHEMBL17446714 | 0.88 | HDAC1 (0.53) | KMT2AHDAC1HDAC2IDO1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
| WO-2023125530-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | KMT2A 2789/4885HDAC1 1697/4885HDAC2 2165/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | KMT2A 1834/4885HDAC1 2469/4885HDAC2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.